<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976339</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC3089</org_study_id>
    <nct_id>NCT00976339</nct_id>
  </id_info>
  <brief_title>Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer</brief_title>
  <official_title>Pilot Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katherine D. Crew</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prevent Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal is for a pilot study of 20 premenopausal women at high risk for breast cancer
      development who will receive high dose vitamin D3, cholecalciferol 20,000 IU (2 capsules)
      weekly, or 30,000 IU (3 capsules) weekly, for 1 year. The primary objective of this study is
      to determine the feasibility of a 1-year intervention of vitamin D in this study population.
      Secondary objectives include evaluating the biologic effects of vitamin D supplementation on
      blood based and image-based biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D has diverse biological effects relevant to carcinogenesis, including known
      cross-talk between the vitamin D receptor (VDR) and insulin-like growth factor (IGF)
      signaling pathways. Based upon observational data, women with serum 25(OH) D levels greater
      than 40-50 ng/ml had a 50% lower risk of breast cancer compared to women with vitamin D
      deficiency.

      Vitamin D is a fat-soluble vitamin which is produced in the body and may come from food
      sources. Epidemiologic studies suggest that vitamin D may influence breast cancer
      development, which has resulted in increased interest in the use of vitamin D for the
      treatment and prevention of breast cancer. Numerous experimental studies have shown that
      vitamin D compounds have anti-carcinogenic properties against breast cancer. Given the
      epidemiologic data and the extensive preclinical evidence of the anti-tumor effects of
      vitamin D, it is therefore reasonable to test the biological effects of high-dose vitamin D
      in early phase clinical trials. The investigators hypothesize that vitamin D3,
      cholecalciferol, will modulate biomarkers of breast cancer risk.

      The relationship between vitamin D status and mammographic density (MD), a strong predictor
      of breast cancer risk, remains unclear [8]. MD refers to the relative proportions of
      radiolucent fat and radiodense epithelial and stromal tissue and may serve as a useful
      intermediate biomarker for breast cancer risk assessment in investigations of potential
      chemopreventive agents. Cross-sectional studies evaluating the association between vitamin D
      intake and MD observed an inverse association among premenopausal women, particularly with
      high serum IGF-1 and low serum IGF binding protein-3 (IGFBP-3). However, there is limited
      data on the biologic effects of vitamin D supplementation for breast cancer prevention in
      human intervention trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Successfully Completed the 1-year Intervention</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mammographic Breast Density</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol 20,000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Cholecalciferol 20,000 IU (2 capsules) weekly for one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol 30,000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Cholecalciferol 30,000 IU (3 capsules) weekly for one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.
Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.</description>
    <arm_group_label>Cholecalciferol 20,000 IU</arm_group_label>
    <arm_group_label>Cholecalciferol 30,000 IU</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elevated risk of breast cancer defined as having at least one of the following: (1)
             Predicted 5-year modified Gail model risk of 1.7% or greater, (2) Lobular carcinoma in
             situ, (3) Known BRCA1 or BRCA2 deleterious mutation carrier, (4) Prior history of
             ductal carcinoma in situ, if no current tamoxifen use or prior radiation to the
             contralateral breast.

          -  Age 21 years or older.

          -  Premenopausal defined as &lt; 6 months since the last menstrual period, no prior
             bilateral oophorectomy, not on estrogen replacement, and serum Follicle-stimulating
             hormone (FSH) values consistent with institutional normal values for the premenopausal
             state.

          -  Normal breast exam and mammogram (BIRADS score of 1 or 2).

          -  Baseline mammographic density â‰¥25% as assessed qualitatively by the mammographer
             (25-50% = &quot;scattered fibroglandular densities&quot;; &gt;50-75% = &quot;heterogeneously dense
             breasts&quot;; &gt;75% = &quot;extremely dense breasts&quot;).

          -  Baseline serum 25-hydroxyvitamin D &lt;32 ng/ml.

          -  Prior tamoxifen use is allowed provided treatment is discontinued at least 28 days
             prior to enrollment.

          -  Willingness to allow submission of core needle breast biopsy for pathology review and
             collection of blood for biomarker analysis and banking.

          -  At least one breast available for imaging and biopsy.

          -  Willingness to not take calcium or vitamin D supplements during the one year
             intervention, due to the potential risk of hypercalcemia/hypercalciuria with high dose
             vitamin D. Premenopausal women who need to take calcium supplementation for any
             medical condition will be excluded from the study. Dietary restrictions on calcium
             intake may be imposed if the subject is found to have borderline high serum or urine
             levels of calcium during the study intervention and a list of dietary sources of
             calcium will be provided.

          -  Normal serum calcium.

          -  No history of kidney stones.

          -  Adequate renal and hepatic function: serum creatinine, bilirubin, aspartate
             aminotransferase (AST), alanine transaminase (ALT) and alkaline phosphatase &lt; 2.0 x
             the institutional upper limit of normal (IULN).

          -  No hypersensitivity reactions to vitamin D.

          -  Performance status of 0 or 1.

          -  Not pregnant or nursing.

          -  Agree to use effective contraception, hormone-based oral contraceptives allowed but
             switching birth control methods is discouraged while on-study.

          -  No significant medical or psychiatric condition that would preclude study completion.

        Exclusion Criteria:

          -  Not meeting one or any of inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Crew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center Herbert Irving Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vieth R. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr. 2006 Apr;136(4):1117-22.</citation>
    <PMID>16549491</PMID>
  </reference>
  <reference>
    <citation>Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001 Feb;73(2):288-94.</citation>
    <PMID>11157326</PMID>
  </reference>
  <reference>
    <citation>Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999 May;69(5):842-56. Review.</citation>
    <PMID>10232622</PMID>
  </reference>
  <reference>
    <citation>Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF. The role of vitamin D in cancer prevention. Am J Public Health. 2006 Feb;96(2):252-61. Epub 2005 Dec 27. Review.</citation>
    <PMID>16380576</PMID>
  </reference>
  <reference>
    <citation>Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7.</citation>
    <PMID>16103450</PMID>
  </reference>
  <reference>
    <citation>John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):399-406.</citation>
    <PMID>10350434</PMID>
  </reference>
  <reference>
    <citation>Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst. 2002 Sep 4;94(17):1301-11.</citation>
    <PMID>12208895</PMID>
  </reference>
  <reference>
    <citation>Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005 May;41(8):1164-9. Epub 2005 Apr 14.</citation>
    <PMID>15911240</PMID>
  </reference>
  <reference>
    <citation>Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2335-9.</citation>
    <PMID>16214913</PMID>
  </reference>
  <reference>
    <citation>Narvaez CJ, Zinser G, Welsh J. Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids. 2001 Mar-May;66(3-5):301-8. Review.</citation>
    <PMID>11179738</PMID>
  </reference>
  <reference>
    <citation>Mathiasen IS, Sergeev IN, Bastholm L, Elling F, Norman AW, JÃ¤Ã¤ttelÃ¤ M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J Biol Chem. 2002 Aug 23;277(34):30738-45. Epub 2002 Jun 18.</citation>
    <PMID>12072431</PMID>
  </reference>
  <reference>
    <citation>Brenner BM, Russell N, Albrecht S, Davies RJ. The effect of dietary vitamin D3 on the intracellular calcium gradient in mammalian colonic crypts. Cancer Lett. 1998 May 15;127(1-2):43-53.</citation>
    <PMID>9619857</PMID>
  </reference>
  <reference>
    <citation>Lowe L, Hansen CM, Senaratne S, Colston KW. Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Recent Results Cancer Res. 2003;164:99-110. Review.</citation>
    <PMID>12908448</PMID>
  </reference>
  <reference>
    <citation>Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1721S-4S. doi: 10.1093/ajcn/80.6.1721S. Review.</citation>
    <PMID>15585794</PMID>
  </reference>
  <reference>
    <citation>Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol. 1976 Jun;126(6):1130-7.</citation>
    <PMID>179369</PMID>
  </reference>
  <reference>
    <citation>Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1133-44. Review.</citation>
    <PMID>9865433</PMID>
  </reference>
  <reference>
    <citation>Lee NA, Rusinek H, Weinreb J, Chandra R, Toth H, Singer C, Newstead G. Fatty and fibroglandular tissue volumes in the breasts of women 20-83 years old: comparison of X-ray mammography and computer-assisted MR imaging. AJR Am J Roentgenol. 1997 Feb;168(2):501-6.</citation>
    <PMID>9016235</PMID>
  </reference>
  <reference>
    <citation>Heywang-KÃ¶brunner SH, Viehweg P, Heinig A, KÃ¼chler C. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol. 1997 Feb;24(2):94-108. Review.</citation>
    <PMID>9097051</PMID>
  </reference>
  <reference>
    <citation>Eng-Wong J, Orzano-Birgani J, Chow CK, Venzon D, Yao J, Galbo CE, Zujewski JA, Prindiville S. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1696-701. doi: 10.1158/1055-9965.EPI-07-2752. Epub 2008 Jun 26.</citation>
    <PMID>18583470</PMID>
  </reference>
  <reference>
    <citation>Arai M, Sasaki A, Saito N, Nakazato Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int. 2005 Mar;55(3):122-9.</citation>
    <PMID>15743320</PMID>
  </reference>
  <reference>
    <citation>Lensmeyer GL, Wiebe DA, Binkley N, Drezner MK. HPLC method for 25-hydroxyvitamin D measurement: comparison with contemporary assays. Clin Chem. 2006 Jun;52(6):1120-6. Epub 2006 Mar 30.</citation>
    <PMID>16574756</PMID>
  </reference>
  <reference>
    <citation>Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 2001 Apr;16(4):605-14.</citation>
    <PMID>11315988</PMID>
  </reference>
  <reference>
    <citation>Lee LG, Connell CR, Bloch W. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res. 1993 Aug 11;21(16):3761-6.</citation>
    <PMID>8367293</PMID>
  </reference>
  <reference>
    <citation>Hershman, D. L., McMahon, D., Irani, D., Cucchiara, G., Crew, K. D., Raptis, G., and Shane, E. High prevalence of vitamin D deficiency in premenopausal women with early-stage breast cancer. Proc Am Soc Clin Oncol, pp. Abst #8568. Atlanta, 2006.</citation>
  </reference>
  <reference>
    <citation>Chlebowski, R. T., Johnson, K. C., Kooperberg, C., Hubbell, A., Lane, D., O'Sullivan, M., Cummings, S., Rohan, T., Khandekar, J., and Investigators, T. W. s. H. I. The Women's Health Initiative randomized trial of calcium plus vitamin D: effects on breast cancer and arthralgias. Proceedings of the American Society of Clinical Oncology 24, pp. LBA6. Atlanta, 2006.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <results_first_submitted>July 27, 2015</results_first_submitted>
  <results_first_submitted_qc>May 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2016</results_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Katherine D. Crew</investigator_full_name>
    <investigator_title>Florence Irving Assistant Professor of Medicine and Assistant Professor of Epidemiology</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Premenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Referrals to the Columbia breast oncology clinic for breast cancer chemoprevention will be recruited medical oncologist or via recruitment flyers. Recruitment letters will be sent to high-risk women who participated in the Metropolitan Breast Cancer Family Registry and Women at Risk (WAR) database.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cholecalciferol 20,000 IU</title>
          <description>Subjects received Cholecalciferol 20,000 IU weekly for 1 year.</description>
        </group>
        <group group_id="P2">
          <title>Cholecalciferol 30,000 IU</title>
          <description>Subjects received Cholecalciferol 30,000 IU weekly for one year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cholecalciferol 20,000 IU</title>
          <description>Subjects received Cholecalciferol 20,000 IU weekly, for 1 year</description>
        </group>
        <group group_id="B2">
          <title>Cholecalciferol 30,000 IU</title>
          <description>Subjects received Cholecalciferol 30,000 IU weekly, for 1 year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&gt; 21 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Successfully Completed the 1-year Intervention</title>
        <time_frame>1 year</time_frame>
        <population>Data for this study (NCT00976339) is combined with the data for another study (NCT00859651); see NCT00859651 for combined results. Investigator is unable to determine the subject data that should be entered for this study alone, since subject data was combined for the purpose of data analysis. Data for this study alone was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 20,000 IU</title>
            <description>Subjects received Cholecalciferol 20,000 IU weekly 1 year</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 30,000 IU</title>
            <description>Subjects received Cholecalciferol 30,000 IU weekly 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Successfully Completed the 1-year Intervention</title>
          <population>Data for this study (NCT00976339) is combined with the data for another study (NCT00859651); see NCT00859651 for combined results. Investigator is unable to determine the subject data that should be entered for this study alone, since subject data was combined for the purpose of data analysis. Data for this study alone was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mammographic Breast Density</title>
        <time_frame>1 year</time_frame>
        <population>Data for this study (NCT00976339) is combined with the data for another study (NCT00859651); see NCT00859651 for combined results. Investigator is unable to determine the subject data that should be entered for this study alone, since subject data was combined for the purpose of data analysis. Data for this study alone was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 20,000 IU</title>
            <description>Subjects received Cholecalciferol 20,000 IU weekly, for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 30,000 IU</title>
            <description>Subjects received Cholecalciferol 30,000 IU weekly, for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mammographic Breast Density</title>
          <population>Data for this study (NCT00976339) is combined with the data for another study (NCT00859651); see NCT00859651 for combined results. Investigator is unable to determine the subject data that should be entered for this study alone, since subject data was combined for the purpose of data analysis. Data for this study alone was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Data for this study (NCT00976339) is combined with the data for another study (NCT00859651); see NCT00859651 for combined results. Investigator is unable to determine the subject data that should be entered for this study alone, since subject data was combined for the purpose of data analysis. Data for this study alone was not analyzed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cholecalciferol 20,000 IU</title>
          <description>Subjects received Cholecalciferol 20,000 IU weekly 1 year</description>
        </group>
        <group group_id="E2">
          <title>Cholecalciferol 30,000 IU</title>
          <description>Subjects received Cholecalciferol 30,000 IU weekly 1 year</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data for this study (NCT00976339) is combined with the data for another study (NCT00859651); see NCT00859651 for combined results. Data for this study alone was not analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Katherine Crew</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-1732</phone>
      <email>kd59@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

